Data published in the journal Diabetes Care suggests THCV is positively associated with glycemic control in type 2 diabetes. In the randomized and placebo-controlled study, investigators from the University of Nottingham, School of Medicine administered placebo or different cannabinoids, like CBD, THCV, or a combination of the two, twice a day over the course of 13 weeks to 62 non-insulin dependent participants with Type 2 diabetes. THCV alone decreased fasting plasma glucose levels and improved pancreatic cell function. Other treatments offered undistinguishable metabolic effects. The study concluded, “THCV could represent a new therapeutic agent in glycemic control in subjects with type 2 diabetes.”
This information has been brought to you by the Daily Chronic and approved by our Chief Medical Officer.